Navigation Links
Anaphore Appoints Paul A. Grayson President and CEO

LA JOLLA, Calif., June 20, 2011 /PRNewswire/ -- Anaphore Inc. today announced the appointment of Paul A. Grayson as president and CEO. A life sciences executive with an extensive track record of success in business development and financial transactions for emerging biopharmaceutical companies, Grayson joins Anaphore as it focuses its efforts on the establishment of collaborations with pharmaceutical companies for the discovery and development of novel Atrimer therapeutics. He replaces Katherine S. Bowdish, Ph.D., a co-founder of Anaphore, who will continue to serve the company as a consultant.

"I am proud of the collective accomplishments of the Anaphore team from inception to date including significantly advancing the core platform technology, programs, and forging a critical partnership," said Kathy Bowdish.  "I am confident of the team's ability to execute under Paul's direction as the company embarks in this next exciting stage in its evolution."

"The addition of Paul reflects Anaphore's movement into its next phase of development," said Russell G. Greig, Ph.D., the company's executive chairman. "His deal-making experience and leadership qualities will bring a new dimension to the company as we increase our efforts to unlock the value of our technology platform. We are grateful to Kathy for her success in building a top-notch scientific team and advancing the technology to this sophisticated stage."

Grayson commented, "I've had the opportunity to evaluate many leadership opportunities in the industry over the past months. Anaphore's Atrimer technology caught my attention and stood out as an innovative approach to tackling diseases that were out of reach because of limitations with today's protein drugs.  I am excited to join the company at its current stage and view this as an opportunity that is destined for success."

Grayson previously served as CEO of Fate Therapeutics, a San Diego-based, privately held biopharmaceutical company focused on the development of therapies that act through stem cell modulation.  Before this, he was managing director of Sanderling Ventures where he was a founding board member of multiple portfolio companies including: Calcimedica, Taligen Therapeutics (acquired by Alexion Pharmaceuticals), and Naviscan.  Prior to Sanderling, Grayson served as the founding Chairman and CEO of Senomyx Inc. and part of the founding management team of Aurora Biosciences (acquired by Vertex).

About Anaphore

Anaphore is developing a new class of protein pharmaceuticals to address significant unmet medical needs for patients with serious diseases. The company's Atrimer technology platform originates in tetranectin, a human plasma protein of trivalent structure. Each of the three binding domains comprises five distinct amino-acid loops that can be programmed to bind potently and specifically to virtually any target of interest.  Atrimer therapeutics potentially offer biological, manufacturing, and commercial advantages over currently marketed therapies. Atrimer protein therapeutics are protected by intellectual property, including multiple patent families.

Anaphore's initial therapeutic focus is immunology and oncology. In collaboration with select partners, Anaphore is committed to realizing the full promise of Atrimer therapeutics against targets in a wide range of therapeutic areas, including rare diseases.

Anaphore recently formed a partnership with Mitsubishi Tanabe Pharma Corporation to discover and develop Atrimer drug candidates for the treatment of autoimmune disorders. Since its founding in 2008, Anaphore has raised $38 million in financing from top-tier biotechnology investors 5AM Ventures, Versant Ventures, Apposite Capital LLP, SR One, Merck Serono Ventures and Aravis SA.

For more information please visit

Media Contact:
Ian Stone or David Schull
Russo Partners, LLC

SOURCE Anaphore
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Innerscope Research(R) Appoints Digital Leader, Andre Marquis, as Senior Vice President of Sales and Marketing
2. ID Analytics Appoints Chief Information Officer
3. ID Analytics Appoints Chief Information Officer
4. Innerscope Research(R) Appoints Digital Leader, Andre Marquis, as Senior Vice President of Sales and Marketing
5. BIO-key(R) Appoints Cecilia Welch as Chief Financial Officer
6. Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative
7. Global Rainmakers Appoints James M. Demitrieus as Chief Operating Officer
8. Global Rainmakers Appoints James M. Demitrieus as Chief Operating Officer
9. Hoyos Group Appoints Anthony Antolino as Chief Marketing Officer
10. The Science Coalitions 10 questions for the presidential debate
11. Haag honored with Presidential Early Career Scientists Award
Post Your Comments:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
Breaking Biology Technology: